Click on a filter below to refine your search. Remove a filter to broaden your search.
Estimated mean change from baseline in HbA1c was −2.1% with tirzepatide, which met noninferiority criteria and achieved superiority.
Significant differences in mean overall CVH scores were based on Life’s Essential 8 by sex, age and racial/ethnic group.
Mean changes in HbA1c were significantly greater for semaglutide 25 mg or 50 mg versus 14 mg.
No significant difference was seen in mean weight loss at 12 months with time-restricted eating and daily calorie restriction.
Patients treated with dasatinib had a mean reduction in serum glucose concentration and a relative decrease in body weight.
Solriamfetol was found to be well-tolerated with no significant effect on mean heart rate or systolic or diastolic blood pressure.
The mean length was 10.7 years by the prevalence/incidence method and 10.1 years by the Markov chain Monte Carlo model method,
A mean of 19.5, 17.1 and 43.3% of participants did not maintain continuity of use of glucose, blood pressure or lipid medications.
In a Scottish cohort, mean frailty decreased as the Disease Activity Score in 28 joints lessened over time with treatment.
Initiators of statins aged 75 years or older had a higher mean percentage reduction than those younger than 50 years.